Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct;34(5):559-64.
doi: 10.1097/JCP.0000000000000180.

Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation

Affiliations
Free PMC article

Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation

Colin Cameron et al. J Clin Psychopharmacol. 2014 Oct.
Free PMC article

Abstract

Nabilone is a synthetic cannabinoid that has shown promise for the treatment of posttraumatic stress disorder (PTSD)-related insomnia and nightmares as well as efficacy in the management of chronic pain. It has also been proposed for harm reduction in cannabis dependence. Its effectiveness for management of concurrent disorders in seriously mentally ill correctional populations has not been evaluated. This retrospective study of 104 male inmates with serious mental illness prescribed nabilone analyzes the indications, efficacy, and safety of its use. Medications discontinued with the initiation of nabilone were also reviewed. The results showed nabilone targeting a mean of 3.5 indications per patient, thus likely reducing polypharmacy risk. The mean final dosage was 4.0 mg. Results indicated significant improvement in PTSD-associated insomnia, nightmares, PTSD symptoms, and Global Assessment of Functioning and subjective improvement in chronic pain. Medications associated with greater risk for adverse effects or abuse than nabilone were often able to be discontinued with the initiation of nabilone, most often antipsychotics and sedative/hypnotics. There was no evidence of abuse within this high-risk population or reduction of efficacy when nabilone was given in powder form with water rather than as a capsule. This study supports the promise of nabilone as a safe, effective treatment for concurrent disorders in seriously mentally ill correctional populations. Prospective, randomized controlled trials are required to confirm our preliminary results. Follow-up in the community will be required to confirm effectiveness in harm reduction.

PubMed Disclaimer

Conflict of interest statement

No funding was received for this study.

Figures

FIGURE 1
FIGURE 1
DSM-IV-TR Axis I diagnoses.
FIGURE 2
FIGURE 2
Indications for nabilone (all off-label).
FIGURE 3
FIGURE 3
Sleep effects. Hours sleep per night = mean number of hours/night, nightmares per week = nights with nightmares/week. Pre nabilone = week prior to starting. Post nabilone = week after final dose was achieved.
FIGURE 4
FIGURE 4
Posttraumatic Checklist–Civilian version and GAF Scores. Pre nabilone = time of admission. Post nabilone = time of discharge.
FIGURE 5
FIGURE 5
Number of medications discontinued.

References

    1. Earlywine M. Chapter 1: Highlights in the history of cannabis. In: Understanding Marijuana: A New Look at the Scientific Evidence. Oxford: Oxford University Press; 2002; 3– 28
    1. Grotenhermen F, Muller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int. 2012; 109; 29– 30:495–501 - PMC - PubMed
    1. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol. 2006; 105; 1– 2:1-25 - PubMed
    1. Repchinsky C. Compendium of Pharmaceuticals & Specialities. Ottawa, Ontario, Canada: Canadian Pharmacists Association; 2013
    1. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain: a systematic review of randomized trials. Br J Clin Pharmacol. 2011; 72 (5): 735– 744 - PMC - PubMed

MeSH terms